Arthur Taveras's most recent trade in X4 Pharmaceuticals Inc was a trade of 230,645 Common Stock done . Disclosure was reported to the exchange on Oct. 4, 2024.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
X4 Pharmaceuticals Inc | Arthur Taveras | Chief Scientific Officer | 04 Oct 2024 | 230,645 | 464,946 (2%) | 1% | 0 | Common Stock | ||
X4 Pharmaceuticals Inc | Arthur Taveras | Chief Scientific Officer | 04 Oct 2024 | 76,920 | 388,026 (2%) | 0% | 0.6 | 43,306 | Common Stock | |
X4 Pharmaceuticals Inc | Arthur Taveras | Chief Scientific Officer | 11 Mar 2024 | 14,235 | 234,301 (1%) | 0% | 0.9 | 12,552 | Common Stock | |
X4 Pharmaceuticals Inc | Taveras Arthur | Chief Scientific Officer | 13 Feb 2024 | 428,248 | 428,248 | - | - | Stock Appreciation Right | ||
X4 Pharmaceuticals Inc | Arthur Taveras | Chief Scientific Officer | 12 Feb 2024 | 787 | 248,536 (1%) | 0% | 1.0 | 793 | Common Stock | |
X4 Pharmaceuticals Inc | Arthur Taveras | Chief Scientific Officer | 10 Mar 2023 | 16,806 | 86,373 (0%) | 0% | 0.8 | 14,117 | Common Stock | |
X4 Pharmaceuticals Inc | Arthur Taveras | Chief Scientific Officer | 13 Feb 2023 | 928 | 103,179 (0%) | 0% | 0.9 | 863 | Common Stock | |
X4 Pharmaceuticals Inc | Arthur Taveras | Chief Scientific Officer | 07 Nov 2022 | 1,000,000 | 1,000,000 | - | - | Stock Appreciation Right | ||
X4 Pharmaceuticals Inc | Arthur Taveras | Chief Scientific Officer | 01 Mar 2022 | 97,000 | 104,107 (0%) | 0% | 0 | Common Stock | ||
X4 Pharmaceuticals Inc | Arthur Taveras | Chief Scientific Officer | 11 Feb 2022 | 928 | 7,107 (0%) | 0% | 0 | Common Stock | ||
X4 Pharmaceuticals Inc | Arthur Taveras | Chief Scientific Officer | 24 Mar 2021 | 8,035 | 8,035 (0%) | 0% | 0 | Common Stock | ||
X4 Pharmaceuticals Inc | Arthur Taveras | Chief Scientific Officer | 30 Nov 2020 | 121,150 | 121,150 | - | - | Stock Option (right to buy) |